Paul Stoffels, Galapagos CEO (Michael Kovac/Getty Images)
November 3, 2022 04:55 PM EDTUpdated 05:12 PM
People
Deals

'For­ward, faster' and 200 jobs lighter as fi­bro­sis and kid­ney dis­ease get cut, Gala­pa­gos CEO Stof­fels once again spot­lights deals

John Carroll

Editor & Founder

New Gala­pa­gos CEO Paul Stof­fels — best known for his turn as the long­time CSO at J&J — has come up with a three-pronged strat­e­gy to dig …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times